Lord, Abbett & Co. LLC Bellus Health Inc. Transaction History

Lord, Abbett & Co. LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Oct 07, 2024	SELL	$7.14 - $8.53 $2.86 Million - $3.42 Million	-401,220 Reduced 32.37%	838,269 $6.04 Million
Q1 2023 May 12, 2023	SELL	$7.14 - $8.53 $2.86 Million - $3.42 Million	-401,220 Reduced 32.37%	838,269 $6.04 Million
Q4 2022 Oct 07, 2024	BUY	$8.22 - $10.76 $10.2 Million - $13.3 Million	1,239,489 New	1,239,489 $10.2 Million
Q4 2022 Feb 10, 2023	SELL	$8.22 - $10.76 $185,961 - $243,423	-22,623 Reduced 1.79%	1,239,489 $10.2 Million
Q3 2022 Nov 14, 2022	SELL	$8.95 - $12.0 $566,212 - $759,168	-63,264 Reduced 4.77%	1,262,112 $13.3 Million
Q2 2022 Aug 12, 2022	BUY	$6.46 - $10.02 $1.06 Million - $1.64 Million	163,518 Added 14.07%	1,325,376 $12.2 Million
Q1 2022 May 13, 2022	SELL	$5.56 - $7.99 $137,343 - $197,368	-24,702 Reduced 2.08%	1,161,858 $7.99 Million
Q4 2021 Feb 11, 2022	BUY	$5.26 - $8.3 $6.24 Million - $9.85 Million	1,186,560 New	1,186,560 $9.55 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.